379.90 0.00 (0.00%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
Price Range
Today’s Low
0.0
Today’s High
0.0
52 Week Low
305.2
52 Week High
617.0
380.00 0.00 (0.00%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
Price Range
Today’s Low
371.2
Today’s High
382.45
52 Week Low
281.8
52 Week High
614.35
Key Metrics
- Market Cap (In Cr) 5907.74
- Beta 1.74
- Div. Yield (%) 1.35
- P/B 1.11
- TTM P/E 32.8
- Peg Ratio 0.47
- Sector P/E 27.98
- D/E 0.64
- Open Price 0
- Prev Close 379.9
Analysis
Price Analysis
-
1 Week-2.66%
-
3 Months13.07%
-
6 Month-6.65%
-
YTD-36.73%
-
1 Year-37.83%
Risk Meter
- 36% Low risk
- 36% Moderate risk
- 36% Balanced Risk
- 36% High risk
- 36% Extreme risk
Recos
4 Analysts
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- Strong Sell
- 0
- Sell
- 0
- Hold
- 2
- Buy
- 0
- Strong Buy
- 2
Jubilant Pharmova News
From Coal India to Varun Beverages: 13 stocks to turn ex-dividend next week
9 min read . 07 Aug 2022
Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2022
- Total Revenue
- 6130.16
- Selling/ General/ Admin Expenses Total
- 3107.09
- Depreciation/ Amortization
- 381.7
- Other Operating Expenses Total
- 29.93
- Total Operating Expense
- 5305.71
- Operating Income
- 824.45
- Net Income Before Taxes
- 630.45
- Net Income
- 413.94
- Diluted Normalized EPS
- 26.14
- Period
- 2022
- Total Assets
- 9990.87
- Total Liabilities
- 4672.3
- Total Equity
- 5318.56
- Tangible Book Valueper Share Common Eq
- 135.04
- Period
- 2022
- Cashfrom Operating Activities
- 837.54
- Cashfrom Investing Activities
- -380.37
- Cashfrom Financing Activities
- -32.6
- Net Changein Cash
- 481.86
- Period
- 2021
- Total Revenue
- 6098.54
- Selling/ General/ Admin Expenses Total
- 2850.19
- Depreciation/ Amortization
- 426.07
- Other Operating Expenses Total
- -75.43
- Total Operating Expense
- 5001.09
- Operating Income
- 1097.44
- Net Income Before Taxes
- 871.08
- Net Income
- 835.87
- Diluted Normalized EPS
- 38.26
- Period
- 2021
- Total Assets
- 8918.11
- Total Liabilities
- 4176.62
- Total Equity
- 4741.49
- Tangible Book Valueper Share Common Eq
- 113.77
- Period
- 2021
- Cashfrom Operating Activities
- 1707.28
- Cashfrom Investing Activities
- -739.01
- Cashfrom Financing Activities
- -1709.39
- Net Changein Cash
- -728.86
- Period
- 2020
- Total Revenue
- 5975.79
- Selling/ General/ Admin Expenses Total
- 2758.84
- Depreciation/ Amortization
- 431.55
- Other Operating Expenses Total
- -101.59
- Total Operating Expense
- 4800.38
- Operating Income
- 1175.41
- Net Income Before Taxes
- 1012.88
- Net Income
- 898.25
- Diluted Normalized EPS
- 40.43
- Period
- 2020
- Total Assets
- 12521.65
- Total Liabilities
- 6917.77
- Total Equity
- 5603.88
- Tangible Book Valueper Share Common Eq
- 174.72
- Period
- 2020
- Cashfrom Operating Activities
- 1542.94
- Cashfrom Investing Activities
- -327
- Cashfrom Financing Activities
- -1050.37
- Net Changein Cash
- 225.42
- Period
- 2019
- Total Revenue
- 9110.82
- Selling/ General/ Admin Expenses Total
- 3482.21
- Depreciation/ Amortization
- 360.3
- Other Operating Expenses Total
- 54.41
- Total Operating Expense
- 8009
- Operating Income
- 1101.82
- Net Income Before Taxes
- 903.81
- Net Income
- 574.46
- Diluted Normalized EPS
- 48.96
- Period
- 2019
- Total Assets
- 11468.51
- Total Liabilities
- 6659.59
- Total Equity
- 4808.92
- Tangible Book Valueper Share Common Eq
- 134.8
- Period
- 2019
- Cashfrom Operating Activities
- 1121.51
- Cashfrom Investing Activities
- -1011.84
- Cashfrom Financing Activities
- 657.43
- Net Changein Cash
- 761.22
- Period
- 2018
- Total Revenue
- 7557.81
- Selling/ General/ Admin Expenses Total
- 2806.34
- Depreciation/ Amortization
- 324.03
- Other Operating Expenses Total
- 39.23
- Total Operating Expense
- 6450.37
- Operating Income
- 1107.44
- Net Income Before Taxes
- 859.08
- Net Income
- 642.81
- Diluted Normalized EPS
- 45.76
- Period
- 2018
- Total Assets
- 9617.62
- Total Liabilities
- 5531.09
- Total Equity
- 4086.53
- Tangible Book Valueper Share Common Eq
- 94.65
- Period
- 2018
- Cashfrom Operating Activities
- 1303.2
- Cashfrom Investing Activities
- -617.7
- Cashfrom Financing Activities
- -901.14
- Net Changein Cash
- -212.27
- Period
- 2017
- Total Revenue
- 6006.32
- Selling/ General/ Admin Expenses Total
- 2231.41
- Depreciation/ Amortization
- 287.71
- Other Operating Expenses Total
- 16.42
- Total Operating Expense
- 4933.04
- Operating Income
- 1073.28
- Net Income Before Taxes
- 737.64
- Net Income
- 575.65
- Diluted Normalized EPS
- 37.41
- Period
- 2017
- Total Assets
- 9040.65
- Total Liabilities
- 5604.6
- Total Equity
- 3436.04
- Tangible Book Valueper Share Common Eq
- 60.28
- Period
- 2017
- Cashfrom Operating Activities
- 1268.49
- Cashfrom Investing Activities
- -450.4
- Cashfrom Financing Activities
- -685.87
- Net Changein Cash
- 117.18
- Period
- 2022-09-30
- Total Revenue
- 1599.5
- Selling/ General/ Admin Expenses Total
- 534.6
- Depreciation/ Amortization
- 93.95
- Other Operating Expenses Total
- 363.05
- Total Operating Expense
- 1531.52
- Operating Income
- 67.98
- Net Income Before Taxes
- 36.4
- Net Income
- 5.49
- Diluted Normalized EPS
- 2.63
- Period
- 2022-09-30
- Total Assets
- 10704.85
- Total Liabilities
- 5229.33
- Total Equity
- 5475.52
- Tangible Book Valueper Share Common Eq
- 128.12
- Period
- 2022-09-30
- Cashfrom Operating Activities
- 208.29
- Cashfrom Investing Activities
- -281.69
- Cashfrom Financing Activities
- -104.32
- Net Changein Cash
- -138.25
- Period
- 2022-06-30
- Total Revenue
- 1451.72
- Selling/ General/ Admin Expenses Total
- 529.18
- Depreciation/ Amortization
- 94.57
- Other Operating Expenses Total
- 343.15
- Total Operating Expense
- 1353.89
- Operating Income
- 97.83
- Net Income Before Taxes
- 69.06
- Net Income
- 47.04
- Diluted Normalized EPS
- 2.96
- Period
- 2022-06-30
- Period
- 2022-06-30
- Period
- 2022-03-31
- Total Revenue
- 1527.53
- Selling/ General/ Admin Expenses Total
- 510.37
- Depreciation/ Amortization
- 100.55
- Other Operating Expenses Total
- 355.05
- Total Operating Expense
- 1380.74
- Operating Income
- 146.8
- Net Income Before Taxes
- 105.67
- Net Income
- 59.55
- Diluted Normalized EPS
- 3.74
- Period
- 2022-03-31
- Total Assets
- 9990.87
- Total Liabilities
- 4672.3
- Total Equity
- 5318.56
- Tangible Book Valueper Share Common Eq
- 135.04
- Period
- 2022-03-31
- Cashfrom Operating Activities
- 837.54
- Cashfrom Investing Activities
- -380.37
- Cashfrom Financing Activities
- -32.6
- Net Changein Cash
- 481.86
- Period
- 2021-12-31
- Total Revenue
- 1310.53
- Selling/ General/ Admin Expenses Total
- 524.54
- Depreciation/ Amortization
- 93.33
- Other Operating Expenses Total
- 318.34
- Total Operating Expense
- 1209.62
- Operating Income
- 100.91
- Net Income Before Taxes
- 70.23
- Net Income
- 50.99
- Diluted Normalized EPS
- 3.2
- Period
- 2021-12-31
- Period
- 2021-12-31
- Period
- 2021-09-30
- Total Revenue
- 1657.45
- Selling/ General/ Admin Expenses Total
- 509.31
- Depreciation/ Amortization
- 99.78
- Other Operating Expenses Total
- 369.42
- Total Operating Expense
- 1417.73
- Operating Income
- 239.72
- Net Income Before Taxes
- 208.04
- Net Income
- 142.84
- Diluted Normalized EPS
- 8.97
- Period
- 2021-09-30
- Total Assets
- 9482.04
- Total Liabilities
- 4373.54
- Total Equity
- 5108.5
- Tangible Book Valueper Share Common Eq
- 129.86
- Period
- 2021-09-30
- Cashfrom Operating Activities
- 553.45
- Cashfrom Investing Activities
- -125.46
- Cashfrom Financing Activities
- -90.84
- Net Changein Cash
- 355.23
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Technical
Moving Average
SMA
- 5 Day379.59
- 10 Day380.09
- 20 Day382.85
- 50 Day358.66
- 100 Day352.79
- 300 Day381.86
Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Granules India
- 334
- 0
- 0
- 381.25
- 227
- 8145.95
- Procter & Gamble Health
- 4159.5
- 0
- 0
- 5479.9
- 3883
- 6794.46
- Jubilant Pharmova
- 379.9
- 0
- 0
- 617
- 305.2
- 5907.74
- Caplin Point Laboratories
- 738.2
- 0
- 0
- 888.45
- 626.3
- 5769.18
- Glenmark Life Sciences
- 428.3
- 0
- 0
- 637.7
- 375
- 5310.94
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Granules India
- 20.1
- 3.23
- 19.17
- 12.14
- Procter & Gamble Health
- 34.42
- 11.02
- -
- -
- Jubilant Pharmova
- 14.2
- 1.11
- 11.9
- 8.04
- Caplin Point Laboratories
- 19.39
- 3.89
- 27.06
- 25.01
- Glenmark Life Sciences
- 12.15
- 2.59
- -
- -
Shareholding
- Category
- Percentage
- No. of shares
- Promoter & Promoter Group Shareholding
- 50.68%
- 80,717,056
- SPB TRUSTEE COMPANY PRIVATE LIMITED & SS TRUSTEE COMPANY PRIVATE LIMITED
- 20.52%
- 32,686,161
- HSB TRUSTEE COMPANY PRIVATE LIMITED & HS TRUSTEE COMPANY PRIVATE LIMITED
- 19%
- 30,257,475
- MAV MANAGEMENT ADVISORS LLP
- 3.15%
- 5,011,400
- NIKITA RESOURCES PRIVATE LIMITED
- 2.2%
- 3,504,540
- JUBILANT ENPRO PRIVATE LIMITED
- 1.33%
- 2,116,000
- JAYTEE PRIVATE LIMITED
- 0%
- 7,600
- MILLER HOLDINGS PTE LTD
- 3.28%
- 5,230,455
- PRIYAVRAT BHARTIA
- 0.88%
- 1,398,010
- HARI SHANKER BHARTIA
- 0.23%
- 360,885
- SHAMIT BHARTIA
- 0.08%
- 129,245
- KAVITA BHARTIA
- 0.01%
- 10,285
- SHYAM SUNDER BHARTIA
- 0%
- 5,000
- Public Shareholding
- 49.26%
- 78,456,943
- EAST BRIDGE CAPITAL MASTER FUND LIMITED
- 4.33%
- 6,896,647
- GOVERNMENT PENSION FUND GLOBAL
- 3.44%
- 5,478,154
- EAST BRIDGE CAPITAL MASTER FUND I LTD
- 3.17%
- 5,043,234
- Others
- 10.57%
- 16,845,061
- Others
- 12.24%
- 19,503,770
- JHUNJHUNWALA RAKESH RADHESHYAM
- 3.61%
- 5,750,000
- JHUNJHUNWALA REKHA RAKESH
- 3.15%
- 5,020,000
- Others
- 2.85%
- 4,545,059
- Others
- 1.55%
- 2,469,574
- INVESTOR EDUCTION AND PROTECTION FUND AUTHORITY MINISTRY OF CORPORATE AFFAIRS
- 1.24%
- 1,967,390
- ABAKKUS EMERGING OPPORTUNITIES FUND-1
- 1.2%
- 1,912,681
- Others
- 0.01%
- 15,681
- Others
- 0.92%
- 1,469,897
- HUF
- 0.41%
- 647,818
- Unclaimed or Suspense or Escrow Account
- 0.1%
- 152,615
- Clearing Members
- 0.03%
- 49,067
- Trusts
- 0.01%
- 9,604
- Others
- 0.39%
- 623,005
- Others
- 0.03%
- 45,675
- Others
- 0.01%
- 8,568
- Others
- 0%
- 2,965
- Others
- 0%
- 478
- Non Promoter - Non Public shareholder
- 0.07%
- 107,140
- Others
- 0.07%
- 107,140
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 21-Oct-22
- Quarterly Results
- 02-Aug-22
- Quarterly Results
- 27-May-22
- Audited Results & Final Dividend
- 04-Feb-22
- Quarterly Results
- 22-Oct-21
- Quarterly Results
- 23-Jul-21
- Quarterly Results
- 04-Jun-21
- Audited Results & Final Dividend
- 05-Feb-21
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 18-May-22
- 18-Apr-22
- POM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 27-May-22
- -
- -
- 5
- 04-Jun-21
- 06-Aug-21
- 05-Aug-21
- 5
No recent bonus announcements.
No recent splits available.
No recent rights issue declared.
Company Profile
ABOUT Jubilant Pharmova
- Industry Biotechnology & Drugs
- ISIN INE700A01033
- BSE Code 530019
- NSE Code JUBLPHARMA
Jubilant Pharmova Limited is an integrated global pharmaceutical and life sciences company. The Company's segments include Pharmaceuticals, Contract Research and Development Services and Proprietary Novel Drugs. The Pharmaceuticals segment, through wholly owned subsidiary Jubilant Pharma Limited, is engaged in manufacture and supply of active pharmaceutical ingredients (APIs), solid dosage formulations, radiopharmaceuticals, allergy therapy products and contract manufacturing of sterile injectables and non-sterile products through six manufacturing facilities in India, United States and Canada and a network of approximately 48 radio pharmacies in the United States. The Contract Research and Development Services segment provides drug discovery and development services as well as clinical data software and service solutions. The Proprietary Novel Drugs segment is a patient-focused biopharmaceutical business working to address unmet medical needs in oncology and autoimmune diseases.
MANAGEMENT
- Hari Bhartia Executive Co-Chairman of the Board, Managing Director
- Arun Sharma Head - Group Treasury, Chief Financial Officer
- Arvind Chokhany Group Chief Financial Officer, Whole-Time Director
- Syed Kazmi President and Chief Executive Officer of Jubilant Therapeutics Inc
- Rohini Seth Chief Human Resource Officer
- Umesh Mehta Chief Information Officer
- Rajiv Shah Compliance Officer, Company Secretary
- Ajay Khanna Group Ombudsperson, Group Chief - Strategic and Public Affairs
- K V S Kumar Chief Sustainability Officer
Company Summary
JUBILANT PHARMOVA SUMMARY
Jubilant Pharmova is trading 0.00% lower at Rs 379.90 as compared to its last closing price. Jubilant Pharmova has been trading in the price range of 0.0 & 0.0. Jubilant Pharmova has given -36.73% in this year & -2.66% in the last 5 days.
Jubilant Pharmova has TTM P/E ratio 32.8 as compared to the sector P/E of 27.98. There are 4 analysts who have initiated coverage on Jubilant Pharmova. There are 2 analysts who have given it a strong buy rating & 0 analysts have given it a buy rating. 0 analysts have given the stock a sell rating.
The company posted a net profit of 5.49 Crores in its last quarter.
Listed peers of Jubilant Pharmova include Granules India (0%), Procter & Gamble Health (0%), Jubilant Pharmova (0%) etc.
FAQs about Jubilant Pharmova
Jubilant Pharmova is trading at 379.90 as on -. This is 0.00% lower as compared to its previous closing price of 379.9
The market capitalization of Jubilant Pharmova is 5907.74 Cr as on -.
The average broker rating on Jubilant Pharmova is Buy. The breakup of analyst rating is given below -
- 0 analysts have given a strong sell rating
- 0 analysts have given a sell rating
- 2 analysts have given a hold rating
- 0 analysts have given a buy rating
- 2 analysts have given a strong buy rating
The 52 wk high for Jubilant Pharmova is 617.0 whereas the 52 wk low is 305.2
Jubilant Pharmova can be analyzed on the following key metrics -
- TTM P/E: 32.8
- Sector P/E: 27.98
- Dividend Yield: 1.35%
- D/E ratio: -
Jubilant Pharmova reported a net profit of 413.94 Cr in 2022.
